Cargando…
The Envelope (E) Protein of SARS-CoV-2 as a Pharmacological Target
The COVID-19 pandemic caused by the SARS-CoV-2 virus is still a global health concern. Several spike (S) protein-based vaccines have been developed that efficiently protect the human population against severe forms of COVID-19. However, some SARS-CoV-2 variants of concern (VOCs) have emerged that ev...
Autor principal: | Santos-Mendoza, Teresa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10143767/ https://www.ncbi.nlm.nih.gov/pubmed/37112980 http://dx.doi.org/10.3390/v15041000 |
Ejemplares similares
-
Mutational insights into the envelope protein of SARS-CoV-2
por: Rahman, M. Shaminur, et al.
Publicado: (2021) -
SARS-CoV-2 envelope protein topology in eukaryotic membranes
por: Duart, Gerard, et al.
Publicado: (2020) -
Sinapic Acid Suppresses SARS CoV-2 Replication by Targeting Its Envelope Protein
por: Orfali, Raha, et al.
Publicado: (2021) -
The SARS-CoV-2 envelope (E) protein has evolved towards membrane topology robustness
por: Duart, Gerard, et al.
Publicado: (2021) -
Binding of the SARS-CoV-2 envelope E protein to human BRD4 is essential for infection
por: Vann, Kendra R., et al.
Publicado: (2022)